Charles Schwab Investment Management Inc. Has $9.66 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Charles Schwab Investment Management Inc. increased its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 1.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,131,485 shares of the biopharmaceutical company’s stock after buying an additional 21,025 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.72% of Ocular Therapeutix worth $9,663,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Palumbo Wealth Management LLC acquired a new stake in Ocular Therapeutix during the fourth quarter worth about $100,000. China Universal Asset Management Co. Ltd. boosted its holdings in Ocular Therapeutix by 11.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 33,336 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 3,347 shares in the last quarter. Intech Investment Management LLC acquired a new stake in Ocular Therapeutix during the third quarter valued at approximately $422,000. Truist Financial Corp acquired a new stake in Ocular Therapeutix during the fourth quarter valued at approximately $427,000. Finally, Courier Capital LLC acquired a new stake in Ocular Therapeutix during the fourth quarter valued at approximately $482,000. 59.21% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

OCUL has been the topic of a number of recent research reports. JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th. Needham & Company LLC initiated coverage on Ocular Therapeutix in a report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, Royal Bank of Canada initiated coverage on Ocular Therapeutix in a report on Tuesday, March 18th. They set an “outperform” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Ocular Therapeutix currently has an average rating of “Moderate Buy” and an average price target of $16.38.

Insider Buying and Selling

In related news, insider Donald Notman sold 11,119 shares of the business’s stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $7.81, for a total value of $86,839.39. Following the completion of the transaction, the insider now owns 193,444 shares in the company, valued at $1,510,797.64. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the business’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the completion of the transaction, the insider now owns 3,520,318 shares of the company’s stock, valued at $24,184,584.66. This trade represents a 0.61 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock worth $283,772 in the last quarter. Insiders own 3.50% of the company’s stock.

Ocular Therapeutix Stock Up 0.9 %

Shares of OCUL opened at $7.51 on Friday. The company has a market capitalization of $1.19 billion, a P/E ratio of -5.69 and a beta of 1.34. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. Ocular Therapeutix, Inc. has a one year low of $4.06 and a one year high of $11.78. The business’s 50 day simple moving average is $7.57 and its 200-day simple moving average is $8.78.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05). Ocular Therapeutix had a negative return on equity of 45.18% and a negative net margin of 283.74%. The business had revenue of $17.08 million during the quarter, compared to analyst estimates of $16.89 million. As a group, sell-side analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.